Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 397Dementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics

Open access

Abstract

A major recent discovery was the identification of an expansion of a non-coding GGGGCC hexanucleotide repeat in the C9ORF72 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Mutations in two other genes are known to account for familial frontotemporal dementia: microtubule-associated protein tau and progranulin. Although imaging features have been previously reported in subjects with mutations in tau and progranulin, no imaging features have been published in C9ORF72. Furthermore, it remains unknown whether there are differences in atrophy patterns across these mutations, and whether regional differences could help differentiate C9ORF72 from the other two mutations at the single-subject level. We aimed to determine the regional pattern of brain atrophy associated with the C9ORF72 gene mutation, and to determine which regions best differentiate C9ORF72 from subjects with mutations in tau and progranulin, and from sporadic frontotemporal dementia. A total of 76 subjects, including 56 with a clinical diagnosis of behavioural variant frontotemporal dementia and a mutation in one of these genes (19 with C9ORF72 mutations, 25 with tau mutations and 12 with progranulin mutations) and 20 sporadic subjects with behavioural variant frontotemporal dementia (including 50% with amyotrophic lateral sclerosis), with magnetic resonance imaging were included in this study. Voxel-based morphometry was used to assess and compare patterns of grey matter atrophy. Atlas-based parcellation was performed utilizing the automated anatomical labelling atlas and Statistical Parametric Mapping software to compute volumes of 37 regions of interest. Hemispheric asymmetry was calculated. Penalized multinomial logistic regression was utilized to create a prediction model to discriminate among groups using regional volumes and asymmetry score. Principal component analysis assessed for variance within groups. C9ORF72 was associated with symmetric atrophy predominantly involving dorsolateral, medial and orbitofrontal lobes, with additional loss in anterior temporal lobes, parietal lobes, occipital lobes and cerebellum. In contrast, striking anteromedial temporal atrophy was associated with tau mutations and temporoparietal atrophy was associated with progranulin mutations. The sporadic group was associated with frontal and anterior temporal atrophy. A conservative penalized multinomial logistic regression model identified 14 variables that could accurately classify subjects, including frontal, temporal, parietal, occipital and cerebellum volume. The principal component analysis revealed similar degrees of heterogeneity within all disease groups. Patterns of atrophy therefore differed across subjects with C9ORF72, tau and progranulin mutations and sporadic frontotemporal dementia. Our analysis suggested that imaging has the potential to be useful to help differentiate C9ORF72 from these other groups at the single-subject level.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/aws001

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Results of the voxel-based morphometry analysis of grey matter volume. (A) Patterns of grey matter loss in MAPT, GRN, C9ORF72 and sporadic FTD groups compared with controls, at P < 0.05 (corrected for multiple comparisons using family-wise error). (B) Differences in grey matter volume between the C9ORF72 group and the other disease groups, at P < 0.001 (uncorrected for multiple comparisons). Results are shown in 3D renderings of the brain.
Figure 1 Results of the voxel-based morphometry analysis of grey matter volume. (A) Patterns of grey matter loss in MAPT, GRN, C9ORF72 and sporadic FTD groups compared with controls, at P < 0.05 (corrected for multiple comparisons using family-wise error). (B) Differences in grey matter volume between the C9ORF72 group and the other disease groups, at P < 0.001 (uncorrected for multiple comparisons). Results are shown in 3D renderings of the brain.CC BY-NC · PubMed Central
Figure 2 Box plots of all variables selected in the penalized multinomial logistic regression model as best for differentiating disease groups. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest.
Figure 2 Box plots of all variables selected in the penalized multinomial logistic regression model as best for differentiating disease groups. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest.CC BY-NC · PubMed Central
Figure 3 Box plots of variables that were not selected in the penalized multinomial logistic regression model as useful for differentiating disease groups, and hence not shown in Fig. 2. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest.
Figure 3 Box plots of variables that were not selected in the penalized multinomial logistic regression model as useful for differentiating disease groups, and hence not shown in Fig. 2. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest.CC BY-NC · PubMed Central
Figure 4 Coefficients for the 14 variables that were retained in the final penalized multinomial logistic regression for the MAPT, GRN, C9ORF72 and sporadic FTD groups. A negative coefficient means that lower values (i.e. more atrophy) on that variable increases the estimated probability of being in that group, holding all other variables constant. L = left; R = right.
Figure 4 Coefficients for the 14 variables that were retained in the final penalized multinomial logistic regression for the MAPT, GRN, C9ORF72 and sporadic FTD groups. A negative coefficient means that lower values (i.e. more atrophy) on that variable increases the estimated probability of being in that group, holding all other variables constant. L = left; R = right.CC BY-NC · PubMed Central
Figure 5 Plots showing the estimated probability of MAPT, GRN, C9ORF72 and sporadic FTD according to volume for each of the 14 variables that were retained in the final model. In each panel, the adjustment covariates are set to their mean values. L = left; R = right; ROI = region of interest.
Figure 5 Plots showing the estimated probability of MAPT, GRN, C9ORF72 and sporadic FTD according to volume for each of the 14 variables that were retained in the final model. In each panel, the adjustment covariates are set to their mean values. L = left; R = right; ROI = region of interest.CC BY-NC · PubMed Central
Figure 6 Plot of the cumulative proportion of variability explained by each principal component for the C9ORF72, MAPT, GRN and sporadic FTD groups.
Figure 6 Plot of the cumulative proportion of variability explained by each principal component for the C9ORF72, MAPT, GRN and sporadic FTD groups.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Research works printed but not linked: 2

  1. 2010, J STAT SOFTWARE, 33, 1
  2. van Swieten, 1999, Annals of neurology, 46, 617, 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I · doi:10.1002/1531-8249(199910)46:4<617::aid-ana10>3.0.co;2-i

Cited by

See all 397

Metadata

Authors
Whitwell, J. L., Weigand, S. D., Boeve, B. F., Senjem, M. L., Gunter, J. L., DeJesus-Hernandez, M., Rutherford, N. J., Baker, M., Knopman, D. S., Wszolek, Z. K., Parisi, J. E., Dickson, D. W., Petersen, R. C., Rademakers, R., Jack, C. R., & Josephs, K. A.
Affiliations
Mayo Clinic (US)
Corresponding author
Whitwell, J. L.
Venue
Brain
Published
2012-02-24
Volume
135
Issue
3
Pages
794-806
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2021422157
Cited by
397
References
64
Citations by year
2026: 6 · 2025: 15 · 2024: 14 · 2023: 15 · 2022: 21 · 2021: 22 · 2020: 24 · 2019: 31 · 2018: 29 · 2017: 29 · 2016: 35 · 2015: 37 · 2014: 36 · 2013: 52 · 2012: 30
FWCI
35.41
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Mayo Foundation for Medical Education and Research (AG17216, AG03949, AG16574)
  • Fondation pour la Recherche sur Alzheimer
  • National Institutes of Health (5u01ag024904-10, 5rc2ns070276-02)
  • National Institute on Aging (U01-AG-024904, R01AG11378, R01AG015866, R01AG26251, P50 AG25711, R21-AG38736, P50‐AG16574, U01AG06786, R56AG026251, R0 1-AG15866, P01-AG-17216, U01AG006786, U01 AG03949, P01AG003949, R21AG038736, R01AG011378, R01AG037491, P50AG025711, R01AG023195, P01AG017216, U24AG026395, R01AG026251, R56 AG26251-03, P50AG016574)
  • National Heart, Lung, and Blood Institute (R01 HL70825, R01HL070825)
  • National Institute on Deafness and Other Communication Disorders (R01DC010367)
  • National Institute of Neurological Disorders and Stroke (RC2-NS070276, NS057567, P50-NS40256, 1RC2-NS070276, P50NS040256, R01NS057567, R01NS065782, R01-NS65782, P50NS072187)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
frontotemporal dementia, C9orf72, tau mutations, progranulin mutations, sporadic frontotemporal dementia, amyotrophic lateral sclerosis, brain atrophy patterns, gray matter atrophy, behavioral variant frontotemporal dementia, hemispheric lateralization, neuroimaging biomarkers, genetic classification, GGGGCC repeat expansion
MeSH terms
C9orf72 Protein, Progranulins, Adult, Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Atlases as Topic, Atrophy, Brain, Demography, DNA-Binding Proteins, Exons, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Neuropsychological Tests, Proteins, Genetic Variation, Reproducibility of Results, Logistic Models, tau Proteins, Age of Onset, Intercellular Signaling Peptides and Proteins, Young Adult, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. https://app.cochat.ai/papers/10.1093/brain/aws001
The paper
Whitwell, J. L., Weigand, S. D., Boeve, B. F., Senjem, M. L., Gunter, J. L., DeJesus-Hernandez, M., Rutherford, N. J., Baker, M., Knopman, D. S., Wszolek, Z. K., Parisi, J. E., Dickson, D. W., Petersen, R. C., Rademakers, R., Jack, C. R., & Josephs, K. A. (2012). Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. https://doi.org/10.1093/brain/aws001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.